Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCAT 2023 | Proposed biomarkers of acute pain in SCD derived from longitudinal transcriptomics

Vivien Sheehan, MD, PhD, Children’s Healthcare of Atlanta and Emory University, Atlanta, GA, discusses her research into the biomarkers associated with acute and chronic pain in patients with sickle cell disease (SCD). As acute and chronic pain are difficult to differentiate and often lead to mistreatment, Dr Sheehan aimed to use longitudinal transcriptomics in SCD patients to determine biomarkers of an individual in their usual state of health and during a pain episode. The biomarkers determined from this study will be validated, and Dr Sheehan hopes that in the future a rapid test for use in the emergency room will allow appropriate treatment to be selected for a patient to alleviate pain. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.